rosiglitazone has been researched along with Acromegaly Due To Pituitary Adenoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gradiser, M; Matovinovic, M; Vrkljan, M | 1 |
| Akin, F; Bastemir, M; Yaylali, GF | 1 |
1 trial(s) available for rosiglitazone and Acromegaly Due To Pituitary Adenoma
| Article | Year |
|---|---|
The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Male; Middle Aged; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Failure | 2007 |
1 other study(ies) available for rosiglitazone and Acromegaly Due To Pituitary Adenoma
| Article | Year |
|---|---|
Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Rosiglitazone; Thiazolidinediones | 2007 |